Ernexa Therapeutics Inc. Common Stock (ERNA) — Analysis Summary
Ernexa Therapeutics Inc. Common Stock (ERNA) has a market cap of $2.58M with year-over-year revenue growth of +0.0%. Net margin stands at -2419.9%. The stock trades at a P/E ratio of -0.2.
Key Takeaways
- Revenue changed +0.0% year-over-year
- Net margin of -2419.9%
- P/E ratio of -0.2
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, ERNA posted revenue growth of +0.0% and trades at a P/E of -0.2.
Ernexa Therapeutics Inc. Common Stock (ERNA)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -9.3x — earnings do not cover interest payments
Revenue fell 100.0% vs the prior period.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
5
Headquarters
CAMBRIDGE, MA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.